Core Insights - The company reported a revenue of 4.41% growth year-on-year for the first three quarters of 2025, reaching 4.766 billion yuan, with a net profit increase of 10.53% to 1.274 billion yuan [1] - The gross profit margin improved by 3.33 percentage points to 73.69%, driven by stable growth in core product lines and a focus on high-margin categories [1] - The company is actively expanding into new growth areas, particularly targeting the silver economy and men's health sectors, which are expected to provide new growth momentum [3] Financial Performance - For the first three quarters, the company achieved a net cash flow from operating activities of 1.31 billion yuan and basic earnings per share of 1.9781 yuan, reflecting a year-on-year increase of 10.35% [1] - In Q3 alone, the company generated 1.716 billion yuan in revenue, marking an 8.50% increase compared to the same period last year, with a net profit of 456 million yuan, up 10.29% [1] Product Performance - The core product matrix, including Ejiao blocks, compound Ejiao syrup, and Taohua Ji Ejiao cake, continued to show robust growth, solidifying market share [2] - The company is focusing on product innovation and marketing strategies to attract diverse consumer groups, particularly through the introduction of low-sugar certified products [2] Strategic Initiatives - The company is leveraging its partnership with China Resources Group to enhance its strategic transformation and ecosystem development, including a 1 billion yuan investment fund for traditional Chinese medicine [4] - The launch of a flagship health supplement store in Hong Kong marks a significant step in the company's global expansion strategy, aiming to integrate cultural outreach with industry presence [5]

Core Viewpoint - Dong-E E-Jiao reported a revenue of 1.716 billion yuan for Q3 2025, marking an 8.5% year-on-year increase, and a net profit of 456 million yuan, up 10.27% year-on-year [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 4.766 billion yuan, reflecting a 4.41% year-on-year growth [1] - The net profit attributable to shareholders for the same period was 1.274 billion yuan, which represents a year-on-year increase of 10.53% [1]

Core Insights - Dong'e Ejiao reported a revenue of 4.766 billion yuan and a net profit of 1.274 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 10.10% and 10.58% respectively, after excluding retrospective adjustments [1][4] - The company has achieved five consecutive years of high growth since 2020, positioning itself as a benchmark in the traditional Chinese medicine industry [2][3] - The company is implementing the "1238" development strategy under the leadership of Chairman Cheng Jie, focusing on expanding into the health consumption market with new products [2][9] Financial Performance - In the first three quarters of 2025, after retrospective adjustments, revenue growth was 4.41% and net profit growth was 10.53% [4] - Despite the technical decline in revenue growth due to adjustments, the net profit growth remained in double digits, indicating strong operational quality [4] - The company completed a share acquisition in July 2025, which affected financial metrics due to the consolidation of financial statements [3][4] Market Position and Strategy - Dong'e Ejiao is a leading brand in the Chinese herbal medicine sector, with a market share exceeding 70% in the ejiao block category and over 25% in the compound ejiao syrup category [9][10] - The company is diversifying its product offerings, including health products targeting men's health, and has launched several new products in recent years [2][10] - The "1238" strategy emphasizes dual-driven development in pharmaceuticals and health consumer goods, aiming to create a second growth curve [9][10] Leadership and Collaboration - Chairman Cheng Jie has been appointed as the executive director and president of China Resources Pharmaceutical Group, enhancing collaboration between Dong'e Ejiao and the state-owned enterprise [6][7] - Cheng's leadership has contributed to the company's robust growth, with a compound annual growth rate of 21.28% in revenue and 41.29% in net profit over the past three years [7][8] - The integration of resources and expertise from the parent group is expected to support Dong'e Ejiao's sustainable development [8][9] Innovation and Product Development - The company is focusing on innovation in product development, collaborating with universities to establish a scientific evidence system for new product development [11] - New product launches include red ginseng and other health supplements, aimed at enhancing market presence and addressing consumer needs [10][11] - Dong'e Ejiao's strategy includes balancing traditional strengths with innovative breakthroughs to navigate market challenges [11]

Core Viewpoint - Dong'e Ejiao (000423.SZ) reported a year-on-year increase in revenue and net profit for the third quarter of 2025, indicating positive financial performance [1] Financial Performance - The company's operating revenue reached 1.716 billion yuan, representing an 8.50% increase compared to the same period last year [1] - The net profit attributable to shareholders was 456 million yuan, reflecting a year-on-year growth of 10.27% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 368 million yuan, showing a slight increase of 0.06% year-on-year [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) reported a total revenue of RMB 4.766 billion for Dong'e Ejiao for the nine months ending September 30, 2025, representing a year-on-year growth of 4.41% [1] - The net profit for the same period was RMB 1.277 billion, reflecting a year-on-year increase of 10.77% [1] - As of the announcement date, the company directly holds 10.19% of Dong'e Ejiao's shares and approximately 23.50% through its non-wholly owned subsidiary, indicating a total effective control of about 23.50% [1] Financial Performance - Total revenue for Dong'e Ejiao reached RMB 4.766 billion, up 4.41% year-on-year [1] - Net profit amounted to RMB 1.277 billion, showing a growth of 10.77% compared to the previous year [1] - The cash and cash equivalents at the end of the period were RMB 3.238 billion [1] Ownership Structure - The company directly holds 10.19% of Dong'e Ejiao [1] - Through its subsidiary, China Resources Dong'e Ejiao Co., Ltd., the company holds approximately 23.50% [1] - The total effective control of Dong'e Ejiao by the group is approximately 23.50%, classified as a subsidiary [1]

Group 1 - The core point of the article is that Dong'e Ejiao held its 13th meeting of the 11th board of directors on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the first half of 2025, Dong'e Ejiao's revenue composition was as follows: pharmaceutical industry accounted for 97.88%, donkey breeding and trade accounted for 1.11%, and other industries accounted for 1.01% [1] - As of the report date, Dong'e Ejiao's market capitalization was 30.8 billion yuan [1] Group 2 - The article also mentions that Chinese innovative drugs have sold overseas authorizations worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdongfang Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported a revenue of 4.766 billion RMB for the nine months ending September 30, 2025, reflecting a year-on-year increase of 4.41% and a net profit of 1.277 billion RMB, which represents a year-on-year increase of 10.77% [1] Financial Performance - Total revenue reached 4.766 billion RMB, marking a 4.41% increase compared to the previous year [1] - Net profit amounted to 1.277 billion RMB, showing a growth of 10.77% year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 於2025年10月24日，東阿阿膠公佈其截至2025年9月30日止九個月的季度報 告。 東阿阿膠股份有限公司（「東阿阿膠」）為一家於中華人民共和國註冊成立的 公司。東阿阿膠的股份於深圳證券交易所上市。截至本公告日期，東阿阿膠 由華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）直接 持有10.19%股權，通過本公司非全資附屬公司華潤東阿阿膠有限公司持有約 23.50%，本集團實際控制東阿阿膠約23.50%並入賬為本公司的附屬公司。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 東阿阿膠 截至2025年9月30日止九個月的未經審核財務業績 東阿阿膠未經審核財務資料乃根據中國公認會計準則編製，且未經本公司核 數師審閱或審核，在審核過程中可能須予調整。有關財務資料僅限於東阿阿 膠，並不能全面反映本集團的營運或財務狀況。股東及潛在投資者買賣本公 司證券時務請僅慎行事，且不應完全依 ...

Core Viewpoint - Dong'e Ejiao (000423) reported a positive growth in both revenue and net profit for the third quarter of 2025, indicating a strong performance in the market [1] Financial Performance - In Q3 2025, the company achieved a revenue of 1.716 billion yuan, representing a year-on-year increase of 8.5% [1] - The net profit attributable to shareholders for Q3 2025 was 456 million yuan, showing a year-on-year growth of 10.27% [1] - For the first three quarters of 2025, the total revenue reached 4.766 billion yuan, with a year-on-year increase of 4.41% [1] - The net profit attributable to shareholders for the first three quarters was 1.274 billion yuan, reflecting a year-on-year growth of 10.53% [1]

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-56 东阿阿胶股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第 十一届董事会第十三次会议，审议通过了《关于对外捐赠的议案》。现将有关情 况公告如下： 一、对外捐赠事项概述 为深化驴产业科研创新，助力公司原料战略布局，公司拟向中国农业大学教 育基金会捐赠人民币 120 万元。根据《深圳证券交易所股票上市规则》《公司章 程》等相关规定，本议案无需提交股东大会审议。 本次捐赠事项不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 二、对公司的影响 1．第十一届董事会第十三次会议决议； 2．深交所要求的其他文件。 本次对外捐赠，有助于推动构建产学研深度融合的驴产业创新生态体系，实 现公司原料保障可持续发展。该捐赠事项，对公司本期及未来财务状况和经营成 果不构成重大影响，不影响公司正常生产经营活动。 特此公告。 东阿阿胶股份有限公司 董 事 会 二〇二五年十月二十五 ...